prescription drug markets

28
PRESCRIPTION DRUG MARKETS S. Vincent Rajkumar, M.D. Professor of Medicine Mayo Clinic

Upload: others

Post on 22-Feb-2022

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: PRESCRIPTION DRUG MARKETS

PRESCRIPTION DRUG

MARKETS S. Vincent Rajkumar, M.D.

Professor of Medicine

Mayo Clinic

Page 2: PRESCRIPTION DRUG MARKETS

The High Cost of Cancer Drugs and What

We Can Do About It

Mustaqeem Siddiqui, MD

S. Vincent Rajkumar, MD

• 20 trials (8 RCTs)

• Regulatory trials

• Celgene (Thalidomide)

• Takeda (Ixazomib)

• Amgen (Carfilzomib)

• Janssen (Daratumurnab)

2012

Page 3: PRESCRIPTION DRUG MARKETS

Number of new myeloma

patients in the US in 2017: 30,000

Total lifetime costs to treat all patients

diagnosed in 2017: $22.4 billion

Excludes spending on hospital, infusion, laboratory, imaging, physician,

nursing and ancillary costs

Mailankody S. ASCO 2016 Source: Memorial Sloan Kettering Cancer Center

Page 4: PRESCRIPTION DRUG MARKETS

Drug Costs

Rajkumar SV. ASCO Ed Book. 2018

Page 5: PRESCRIPTION DRUG MARKETS

Drug Costs

Appx. Drug Cost Per Year* (U.S. Dollars)

Rajkumar SV. ASCO Ed Book. 2018

Page 6: PRESCRIPTION DRUG MARKETS
Page 7: PRESCRIPTION DRUG MARKETS
Page 8: PRESCRIPTION DRUG MARKETS

All new cancer drugs approved by FDA in 2017: >$100,000/year

Average = $150,000

Page 9: PRESCRIPTION DRUG MARKETS

$ 360 billion (USA)

(~10% healthcare spend)

Cancer Drugs

$50 billion (USA)

$60 billion (Rest of the world)

Page 10: PRESCRIPTION DRUG MARKETS
Page 11: PRESCRIPTION DRUG MARKETS

High Cost of Development

Cost-Benefit of New Drugs

Market Forces will Decide

Stifle Innovation

Asserted Reasons for High Costs

Page 12: PRESCRIPTION DRUG MARKETS

Fig 1. Cost trajectories of targeted therapies. Cumulative change (%) from baseline mean monthly cost by year. General inflation

rates are plotted as black dotted line; health-related inflation is plotted as red dotted line.

Published in: Noa Gordon; Salomon M. Stemmer; Dan Greenberg; Daniel A. Goldstein; JCO 2018, 36, 319-325. DOI:

10.1200/JCO.2016.72.2124.Copyright © 2017 American Society of Clinical Oncology.

Page 13: PRESCRIPTION DRUG MARKETS
Page 14: PRESCRIPTION DRUG MARKETS
Page 15: PRESCRIPTION DRUG MARKETS

30 million

diabetics in the

United States

1.3 million Type I

~30% of diabetics

take insulin

Source: CDC

Page 16: PRESCRIPTION DRUG MARKETS

Why are drug prices so high?

Page 17: PRESCRIPTION DRUG MARKETS

#1: Circumstances

Vulnerable populations willing to pay anything for

access to life-saving drugs

Page 18: PRESCRIPTION DRUG MARKETS

#2

Page 19: PRESCRIPTION DRUG MARKETS

#3: Patent Evergreening

• Discovered 1921

• 1923 First Insulin patented (Patent sold for $3)

• 1946 Improved NPH patented

• 1950s Improved Lente versions patented

• 1970s Improved pure insulins patented

• 1980s Recombinant human insulin patented

• 1990s Analog insulin patented

• 2000s Long acting analog insulin patented

Page 20: PRESCRIPTION DRUG MARKETS

#4: Planned Obsolescence

Greene JA, Riggs KR. N Engl J Med 2015;372:1171

Imatinib

Nilotinib

Page 21: PRESCRIPTION DRUG MARKETS

#5: Barriers to Generic and Biosimilar Entry

FDA obstacles

Lawsuits

Pay for delay

Page 22: PRESCRIPTION DRUG MARKETS

#6: Lock-step Pricing

Page 23: PRESCRIPTION DRUG MARKETS

#7: Middlemen

Business Insider

Page 24: PRESCRIPTION DRUG MARKETS

Why are drug prices so high?

3 reasons unique to the United States

1) Medicare cannot negotiate

2) Ban on personal importation

3) Reimbursement system encourages more expensive

options

Page 25: PRESCRIPTION DRUG MARKETS

Sanofi/Regeneron Amgen

Page 26: PRESCRIPTION DRUG MARKETS

Patients

Co-pay assistance

Pharma

$

Page 27: PRESCRIPTION DRUG MARKETS

The High Cost of Cancer Drugs and What

We Can Do About It

Mustaqeem Siddiqui, MD

S. Vincent Rajkumar, MD

• Nonprofit Generic and biosimilar manufacturers

2012

Page 28: PRESCRIPTION DRUG MARKETS

Questions?